Skip to main content
Clinical Trials/NCT03912870
NCT03912870
Completed
Not Applicable

Interest of Flow Cytometry in Infectious Point of Care: Feasibility Study

Assistance Publique Hopitaux De Marseille1 site in 1 country96 target enrollmentDecember 10, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
A Potential Infectious Respiratory Clinical Syndrome
Sponsor
Assistance Publique Hopitaux De Marseille
Enrollment
96
Locations
1
Primary Endpoint
Variables specifically measured for this study will be the flow cytometry assay of the two biomarkers (CD64, CD169)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this project is to validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity.

This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers.

Detailed Description

The detection and characterization of infectious events is a major challenge for emergency medicine. Thus the possibility of quickly attributing an infectious origin to a febrile and/or inflammatory syndrome makes it possible to treat and refer the patient quickly. In addition, the ability to distinguish bacterial etiology from viral etiology provides a valuable additional indication for the clinician. This of the upmost importance for fragile populations such as elderly patients and in epidemic conditions such as influenza. A new rapid diagnostic guidance solution is proposed by the Beckman Coulter Laboratory with the simultaneous assay of two biomarkers, one allowing the detection of a viral infectious process (CD169), the other of a bacterial infectious process (CD64). The combination of these two biomarkers, measured in 12 minutes by a new generation assay and flow cytometer, represents an opportunity for emergency services. To date, there is no study on the validation of this diagnostic orientation method. We propose to carry out a prospective, observational, non-interventional feasibility study to compare the results of these measurements with the usual diagnostic criteria combining the clinical signs, infectious testing, and biological data.

Registry
clinicaltrials.gov
Start Date
December 10, 2018
End Date
May 11, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient over 18 years of age presenting to the Timone 2 Emergency Department with the association:
  • A fever\> 38 ° C or hypothermia \<36.5 ° C.
  • A potential clinical infectious syndrome is respiratory (cough, sputum, dyspnea), or urinary (potential urinary tract infection), or abdominal (potentially infectious diarrhea, potentially infectious pain syndrome) or neurological (meningitis potential) or cutaneous (erysipelas).

Exclusion Criteria

  • Patients with clinical criteria that may increase other non-specific biomarkers and therefore not allow for subsequent comparison:
  • Known inflammatory and autoimmune disease
  • Infectious chronic viral, fungal or bacterial disease
  • Antibiotic or anti viral treatment prior to admission
  • Immunosuppressive treatment
  • neoplasia
  • Extended burn
  • Recent surgery (\<1 month)

Outcomes

Primary Outcomes

Variables specifically measured for this study will be the flow cytometry assay of the two biomarkers (CD64, CD169)

Time Frame: 96 hours

to validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures

Study Sites (1)

Loading locations...

Similar Trials